February 18, 2024
Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.
Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.
In this March, 2023 conversation, Jeff McIntyre from Global Liver Institute talks with Louise Campbell and Roger Green about key upcomoing regulatory events, including an ICER review of resmetirom and obeticholic acid and an FDA workshop on NITs.
Four leading MASLD patient advocates join Louise Campbell and Roger Green to discuss the role that MASLD patient advocates and others are likely to play in MASH drug access decisions, along with education and informational processes.
Four leading MASLD patient advocates join Louise Campbell and Roger Green to discuss the challenges in patient access and education that will follow the first MASH drug approval. expectations for the resmetirom PDUFA data and, with it, the potential for the first MASH drug approval.
Four leading MASLD patient advocates join Louise Campbell and Roger Green to discuss their expectations for the resmetirom PDUFA data and, with it, the potential for the first MASH drug approval.
Leading MASLD patient advocates Tony Villiotti of NASH kNOWledge, Wayne Eskridge of the Fatty Liver Foundation, Jeff McIntyre of the Global Liver Institute, and Milan Mishkevikj of the European Liver Patients Association join Louise Campbell and Roger Green to share their vision of changes in the MASH world in 2024 along with each organization’s hopes, concerns and plans. The discussion covers the advocates’ hopes and concerns for the year as well as the programs and efforts each considers top priority.
After a month off in January, SurfingMASH returns for the 2024 calendar year. In this last segment of Episode 1, the co-hosts explore the complexities surrounding advertising and accessibility of metabolic agents in the US market, with a particular focus on how these factors might influence public engagement and healthcare provider education.
After a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, the group examines the explosion of telemarketer-driven consumer advertising for GLP-1 agents as anti-obesity medicines and asks what impact this might have on diagnosis, treatment and monitoring of MASH in the US.